All Articles

The MPNs myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET) are associated with a variety of burdensome symptoms (BMC Cancer. 2016;16:167) and reduced survival compared with the general population (PLOS One. 2014;9:e90299).
Read More

Patient navigation has been shown to improve patient engagement and participation in clinical trials and reduce barriers to cancer care.
Read More

Sarah Cannon’s San Antonio market was seeking a way to effectively improve key quality and operational navigation metrics on their monthly Navigation Market Scorecard.
Read More



Cancer patients must juggle doctor appointments; combat treatment side effects, while trying to maintain a sense of normalcy; and handle financial struggles.
Read More

The combination of the mammalian target of rapamycin (mTOR) inhibitor, everolimus, and the aromatase inhibitor, exemestane, is approved for use in postmenopausal women with HR+, HER2– ABC after failure on letrozole or anastrozole treatment.
Read More

This study describes the nurse perspective on the importance of biomarker testing for patients with metastatic non–small cell lung cancer (NSCLC) and identifies best practices and process gaps.
Read More

Endocrine therapy is recommended for patients with hormone receptor–positive (HR+) advanced and metastatic breast cancer without visceral crisis (symptomatic visceral disease).
Read More

Of the 1.6 million individuals annually diagnosed with cancer, 522,166 received chemoradation, with 234,975 developing toxic mucositis and 20% dying within 5 years due largely to mucositis-mediated unplanned treatment breaks.
Read More

Page 217 of 283

Journal of Oncology Navigation & Survivorship
JONS

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
    Profession or Role
    Primary Specialty or Disease State
    Country